Anesthesiology · Pain ManagementTrial Updateclinicalmid-term

Trial Protocol for Liposomal Bupivacaine in Shoulder Arthroscopy Pain Management

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 6:34:41 AM

Assessment confidence: 71% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This trial protocol is significant as it aims to determine the optimal concentration of liposomal bupivacaine for postoperative analgesia, which could enhance recovery protocols in shoulder arthroscopy. The outcomes may influence clinical practices and competitive positioning within the anesthetic market. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 10 ranked evidence items (6 high-relevance).

Strategic Assessment

Results could lead to improved pain management protocols, enhancing patient recovery and positioning the company favorably against competitors in the anesthetic space. The strongest clinical anchor is Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Quality of Recovery in VATS Partial Pneumonectomy (ClinicalTrials.gov), sub-indication match (pain); entity match (liposomal bupivacaine). In pain, 4 regulatory and 0 competitive items passed relevance filtering for liposomal bupivacaine.

Competitive Pressure

The most relevant competitive pressure comes from The trial may provide insights into optimal dosing of liposomal bupivacaine, potentially influencing its use in postoperative pain management and impacting competitors in the analgesia market..

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). Relevant agencies in corpus: FDA, MHRA. The trial results may lead to updates in clinical guidelines and practices, which could affect future regulatory submissions and labeling for liposomal bupivacaine.

Key Risks

Elevated medium regulatory exposure for liposomal bupivacaine could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Improved pain management protocols could enhance market share for liposomal bupivacaine, potentially increasing revenue as hospitals adopt more effective pain management strategies.
Results could lead to improved pain management protocols, enhancing patient recovery and positioning the company favorably against competitors in the anesthetic space.

What Would Change This Assessment

This becomes more urgent if Monitor trial outcomes related to pain relief efficacy and mobility post-surgery, as well as any changes in clinical practice guidelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management
MHRAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Quality of Recovery in VATS Partial Pneumonectomy
ClinicalTrials.govhigh relevance
Sub-indication match (pain); Entity match (liposomal bupivacaine)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govmedium relevance
Entity match (liposomal bupivacaine)
FDA document
View source
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of different liposomal bupivacaine concentrations in ultrasound-guided superior trunk block on postoperative analgesia and mobility: a randomized double-blind controlled trial protocol for shou
PubMedhigh relevance
Sub-indication match (pain); Entity match (liposomal bupivacaine)
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedhigh relevance
Sub-indication match (pain); Entity match (liposomal bupivacaine)
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

liposomal bupivacaine
pain management protocols

Commercial impact

medium

Improved pain management protocols could enhance market share for liposomal bupivacaine, potentially increasing revenue as hospitals adopt more effective pain management strategies.

Regulatory impact

medium

The trial results may lead to updates in clinical guidelines and practices, which could affect future regulatory submissions and labeling for liposomal bupivacaine.

What to watch

Monitor trial outcomes related to pain relief efficacy and mobility post-surgery, as well as any changes in clinical practice guidelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.